drugset / Trial / NCT03057730

A Clinical Trial Testing Root Coverage With Acellular Dermal Matrix in Thin and Thick Gingival Biotypes

NCT03057730

Phase 4 Active not recruiting 34 enrolled Tufts University
Non-randomizedParallel-groupSingle-blindTreatment

Summary

Gingival recession is a common defect among the American population. It is also a major cause for root decay, hypersensitivity, contributes to tooth mobility and low self-esteem. Acellular dermal matrix, a human-derived grafting material has been put on the market for the treatment of gingival recession. Treating gingival recession with this material has been a validated treatment option for years. However, treatment outcomes in two patient populations, namely those with thin biotypes and those with thick biotypes, has not been investigated. This study will observe the primary treatment outcomes in the two patient groups at 5 time points - 3 months, 6 months and 12 months post-surgery to observe short term outcomes; additional 24 months and 48 months post-surgery to observe long term outcomes.

Timeline

Start
2015-08
Primary completion
2025-09
Completion
2025-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AlloDerm Other / unclassified Other

Indications